

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-082-F  
(400/249US)

Serial No.

10/597,755

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**  
Jadhav et al.

**Filing Date:**

August 7, 2006

**Group:**

1645

**U.S. PATENT APPLICATION DOCUMENTS**

Examiner Initial		Document Number	Filing Date	Name	Class	Subclass	Publication Date if Appropriate
	*	US-2002/0086356	03/30/01	Tuschl et al.			07/04/02
	*	US-2002/0151693	02/08/01	Breaker et al.			10/17/02
	*	US-2003/0059944	09/13/02	Lois-Caballe et al.			03/27/03
	*	US-2003/0064945	07/25/01	Akhtar et al.			04/03/03
	*	US-2003/0143732	08/30/02	Fosnaugh et al.			07/31/03
	*	US-2003/0190635	07/25/02	McSwiggen et al.			10/09/03
	*	US-2003/0206887	09/16/02	Morrissey et al.			10/09/03
	*	US-2004/0019001	07/26/02	McSwiggen et al.			01/29/04
	*	US-2004/0161844	11/04/03	Baker et al.			08/19/04
	*	US-2005/0020521	09/25/05	Rana, Tariq M.			01/27/05
	*	US-2005/0182005	05/13/04	Tuschl et al.			02/18/05
	*	US-2005/0227256	11/26/04	Hutvagner et al.			10/13/05

**U.S. PATENT DOCUMENTS**

Examiner Initial		Document Number	Date	Name	Class	Subclass	Filing Date if Appropriate
	*	5,587,471	12/24/96	Cook et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

**FORM PTO-1449**  
(Rev. 2-32)

**U.S. Department of Commerce**  
**Patent and Trademark Office**

**Atty. Docket No.**  
04-082-F  
(400/249US)

**Serial No.**  
10/597,755

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**  
Jadhav et al.

**Filing Date:**  
August 7, 2006

**Group:**  
1645

	*	5,814,620	09/29/98	Robinson et al.			
	*	5,898,031	04/27/99	Crooke, Stanley T.			
	*	5,998,148	12/07/99	Bennett et al.			
	*	5,998,203	12/07/99	Matulic-Adamic et al.			
	*	5,998,206	12/07/99	Cowsert			
	*	6,060,456	05/09/00	Arnold et al.			
	*	6,107,094	08/22/00	Crook, Stanley T.			
	*	6,214,805	04/10/01	Torrence et al.			
	*	6,346,398	02/12/02	Pavco et al.			
	*	6,506,559	01/14/03	Fire et al.			
	*	6,573,099	06/03/03	Graham et al.			
	*	6,824,972	11/30/04	Kenwick et al.			
	*	7,022,828	04/04/06	McSwiggen et al.			
	*	7,078,196	07/18/06	Tuschl et al.			

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
04-082-F  
(400/249US)

Serial No.  
10/597,755

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**  
Jadhav et al.

**Filing Date:**  
August 7, 2006

**Group:**  
1645

**FOREIGN PATENT DOCUMENTS**

		Document Number	Date	Country	Class	Subclas s	Translation	
							Yes	No
	1.	2001240375 (Old Application No. 40375/01)	03/16/01	AU (Graham et al.)				
	2.	2,359,180	08/03/00	CA (Kreutzer et al.)				
	3.	1325955	01/04/02	EP (Klippel-Gese et al.)				
	4.	1389637	08/05/02	EP (Klippel et al.)				
	5.	1144623 B1	01/29/02	EP (Kreutzer et al.)				
	6.	08208687	08/13/96	JP (Hotoda et al.) ABSTRACT ONLY				
	7.	90/14090	11/29/90	WO (Gillespie et al.)				
	8.	94/01550	01/20/94	WO (Agrawal et al.)				
	9.	95/04142	02/09/95	WO (Robinson)				
	10.	99/04819	02/04/99	WO (Klimuk)				
	11.	99/07409	02/18/99	WO (Deschamps de Paillette et al.)				
	12.	99/14226	03/25/99	WO (Wengel et al.)				
	13.	99/32619	07/01/99	WO (Fire et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
04-082-F  
(400/249US)

Serial No.  
10/597,755

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**  
Jadhav et al.

**Filing Date:**  
August 7, 2006

**Group:**  
1645

	14.	99/49029	09/30/99	WO (Graham et al.)				
	15.	99/53050	10/21/99	WO (Waterhouse et al.)				
	16.	99/55857	11/04/99	WO (Beigelman et al.)				
	17.	99/61631	12/02/99	WO (Heifetz et al.)				
	18.	00/01846	01/13/00	WO (Plaetinck et al.)				
	19.	00/21560	04/20/00	WO (Alitalo et al.)				
	20.	00/44895	08/03/00	WO (Kreutzer et al.)				
	21.	00/44914	08/03/00	WO (Li et al.)				
	22.	00/49035	08/24/00	WO (Sheen)				
	23.	00/63364	10/26/00	WO (Pachuk et al.)				
	24.	01/04313	01/18/01	WO (Sathishchandran et al.)				
	25.	01/29058	04/26/01	WO (Mello et al.)				
	26.	01/36646	05/25/01	WO (Zernicka-Goetz et al.)				
	27.	01/38551	05/31/01	WO (Grossniklaus)				
	28.	01/42443	06/14/01	WO (Churikov et al.)				
	29.	01/49844	07/12/01	WO (Driscoll et al.)				
	30.	01/53475	07/26/01	WO (Cogoni et al.)				
	31.	01/68836	09/20/01	WO (Beach et al.)				
	32.	01/70944	09/27/01	WO (Honer et al.)				
	33.	01/70949	09/27/01	WO (Graham et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
04-082-F  
(400/249US)

Serial No.  
10/597,755

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**  
Jadhav et al.

**Filing Date:**  
August 7, 2006

**Group:**  
1645

34.	01/72774	10/04/01	WO (Deak et al.)				
35.	01/75164	10/11/01	WO (Tuschl et al.)				
36.	01/92513	12/06/01	WO (Arndt et al.)				
37.	01/96584	12/20/01	WO (Mushegian et al.)				
38.	01/97850	12/27/01	WO (Siemeister et al.)				
39.	02/07747	01/31/02	WO (King)				
40.	02/10378	02/07/02	WO (Cowser et al.)				
41.	02/22636	03/21/02	WO (Bennett et al.)				
42.	02/38805	05/16/02	WO (Echeverri et al.)				
43.	02/44321	06/06/02	WO (Tuschl et al.)				
44.	02/055692	01/09/02	WO (Kreutzer et al.)				
45.	02/055693	01/09/02	WO (Kreutzer et al.)				
46.	02/096927	12/05/02	WO (Escobedo et al.)				
47.	03/044188	11/21/02	WO (Tei et al.)				
48.	03/064625	08/07/03	WO (Woolf et al.)				
49.	03/064626	08/07/03	WO (Woolf et al.)				
50.	03/068797	08/21/03	WO (Rossi et al.)				
51.	03/070887	08/28/03	WO (McSwiggen et al.)				
52.	03/070896	08/28/03	WO (McSwiggen et al.)				
53.	03/070910	08/28/03	WO (McSwiggen et al.)				

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.  
04-082-F  
(400/249US)

Serial No.  
10/597,755

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**  
Jadhav et al.

**Filing Date:**  
August 7, 2006

**Group:**  
1645

54.	03/074654 (PCT/US03/05028)	09/12/03	WO (McSwiggen et al.)				
55.	03/080638	10/02/03	WO (LaCasse et al.)				
56.	04/029212	04/08/04	WO (Rana, Tariq M.)				
57.	04/043977	05/27/04	WO (Prakush et al.)				
58.	04/048566	11/21/03	WO (Saigo et al.)				
59.	04/072261	08/26/04	WO (Li et al.)				
60.	04/090105	10/21/04	WO (Leake et al.)				
61.	05/049821	11/18/04	WO (Naito et al.)				

**OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc).**

62.	Adah et al., "Chemistry and Biochemistry of 2',5'-Oligoadenylate-Based Antisense Strategy," <i>Current Medicinal Chemistry</i> , 8, 1189-1212 (2001)
63.	Alexeev et al., "Localized in vivo genotypic and phenotypic correction of the albino mutation in skin by RNA-DNA oligonucleotide," <i>Nature Biotechnology</i> , 18:43-47 (2000)
64.	Bahramian et al., "Transcriptional and Posttranscriptional Silencing of Rodent $\alpha 1(I)$ Collagen by a Homologous Transcriptionally Self-Silenced Transgene," <i>Molecular and Cellular Biology</i> , 274-283 (1999)
65.	Bass, "Double-Stranded RNA as a Template for Gene Silencing," <i>Cell</i> , 101, 235-238 (2000)
66.	Bass, "The short answer," <i>Nature</i> 411:428-429 (2001)
67.	Bayard et al., "Increased stability and antiviral activity of 2'-O-phosphoglycerol derivatives of (2'-5')oligo(adenylate)," <i>Eur. J. Biochem.</i> , 142(29):291-298 (1984)
68.	Beigelman et al., "Chemical Modification of Hammerhead Ribozymes," <i>The Journal of Biological Chemistry</i> 270:25702-25708 (1995)

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  04-082-F (400/249US)	<b>Serial No.</b>  10/597,755
<b>SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> Jadhav et al.	
		<b>Filing Date:</b> August 7, 2006	<b>Group:</b> 1645

69.	Bellon et al., "4-Thio-oligo- $\beta$ -D-ribonucleotides: synthesis of $\beta$ -4'-thio-oligouridylates, nuclease resistance, base pairing properties, and interaction with HIV-1 reverse transcriptase," <i>Nucleic Acids Research</i> , 21(7):1587-1593 (1993)
70.	Bernstein et al., "Role for a Bidentate Ribonuclease in the Initiation Step of RNA Interference," <i>Nature</i> 409:363-366 (2001)
71.	Bernstein et al., "The rest is silence," <i>RNA</i> , 7:1509-1521 (2001)
72.	Bitko et al., "Phenotypic silencing of cytoplasmic genes using sequence-specific double-stranded short interfering RNA and its application in the reverse genetics of wild type negative-strand RNA viruses," <i>BMC Microbiology</i> , 1:34 (11 pgs) (2001)
73.	Braasch et al., "Novel Antisense and Peptide Nucleic Acid Strategies for Controlling Gene Expression," <i>Biochemistry</i> , 31:14, 4503-4510 (2002)
74.	Braasch et al., "RNA Interference in Mammalian Cells by Chemically-Modified RNA," <i>Biochemistry</i> , 42, 7967-7975 (2003)
75.	Caplen, Natasha J., "RNAi as a gene therapy approach," <i>Expert Opin. Biol. Ther.</i> , 3(4):575-586 (2003)
76.	Chiu et al., "siRNA function in RNAi: A chemical modification analysis," <i>RNA</i> , 9:1034-1048 (2003)
77.	Claverie, Jean-Michel, "Fewer Genes, More Noncoding RNA," <i>Science</i> , 309, 1529-1530 (2005)
78.	Clemens et al., "The Double-Stranded RNA-Dependent Protein Kinase PKR: Structure and Function," <i>Journal of Interferon and Cytokine Research</i> , 17:503-524 (1997)
79.	Czech, Michael P., "MicroRNAs as Therapeutic Targets," <i>The New England Journal of Medicine</i> , 354, 1194-1195 (2006)
80.	Elbashir et al., "Analysis of gene function in somatic mammalian cells using small interfering RNAs," <i>Methods</i> , 26:199-213 (2002)
81.	Elbashir et al., "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells," <i>Nature</i> 411:494-498 (2001)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> (Rev. 2-32)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  04-082-F (400/249US)	<b>Serial No.</b>  10/597,755
<b>SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)		<b>Applicant:</b> Jadhav et al.  <b>Filing Date:</b> August 7, 2006	
		<b>Group:</b> 1645	

82.	Elbashir et al., "RNA Interference is Mediated by 21- and 22-Nucleotide RNAs," <i>Genes and Development</i> 15:188-200 (2001)
83.	Fire et al., "Potent and Specific Genetic Interference by Double-Stranded RNA in <i>Caenorhabditis Elegans</i> ," <i>Nature</i> 391:806-811(1998)
84.	Fire, "RNA-triggered Gene Silencing," <i>TIG</i> 15:358-363(1999)
85.	Futami et al., "Induction of Apoptosis in HeLa Cells with siRNA Expression Vector Targeted Against bcl-2," <i>Nucleic Acids Research Supplement</i> 2:251-252 (2002)
86.	Hamasaki et al., "Short interfering RNA-directed inhibition of hepatitis B virus replication," <i>FEBS Letters</i> , 543:51-54 (2003)
87.	Hamilton, et al., "A Species of Small Antisense RNA in Posttranscriptional Gene Silencing in Plants," <i>Science</i> , 286, 950-952 (1999))
88.	Hammond et al., "An RNA-Directed Nuclease Mediates Post-Transcriptional Gene Silencing in <i>Drosophila</i> Cells," <i>Nature</i> 404:293-296 (2000)
89.	Hammond et al., "Post-Transcriptional Gene Silencing by Double-Stranded RNA," <i>Nature</i> , 2:110-119 (2001)
90.	Harborth et al., "Sequence, Chemical, and Structural Variation of Small Interfering RNAs and Short Hairpin RNAs and the Effect on Mammalian Gene Silencing," <i>Antisense and Nucleic Acid Drug Development</i> , 13:83-105 (2003)
91.	Hasan et al., "VEGF antagonists," <i>Oncologic, Metabolic &amp; Endocrine</i> , 703-718 (2001)
92.	Holen et al., "Positional effects of short interfering RNAs targeting the human coagulation trigger Tissue Factor," <i>Nucleic Acids Research</i> , 30:8, 1757-1766 (2002)
93.	Hornung et al., "Sequence-specific potent induction of IFN- $\alpha$ by short interfering RNA in plasmacytoid dendritic cells through TLR7," <i>Nature Medicine</i> , 11, 263-270 (2005)
94.	Hutvagner et al., "A Cellular Function for the RNA-Interference Enzyme Dicer in the Maturation of the let-7 Small Temporal RNA," <i>Science</i> 293:834-838 (2001)
95.	Jen et al., "Suppression of gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies," <i>Stem Cells</i> , 18:307-319 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449 (Rev. 2-32)	U.S. Department of Commerce Patent and Trademark Office	Atty. Docket No.  04-082-F (400/249US)	Serial No.  10/597,755
SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT		Applicant: Jadhav et al.	
(Use several sheets if necessary)		Filing Date:  August 7, 2006	Group:  1645

96.	Judge et al., "Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA," <i>Nature Biotechnology</i> , 23(4):457-462 (2005)
97.	Kawaski et al., "Uniformly Modified 2'-Modified 2'-Deoxy-2'-fluoro Phosphorothioate Oligonucleotides as Nuclease-Resistant Antisense Compounds with High Affinity and Specificity for RNA Targets," <i>J. Med. Chem.</i> , 36, 831-841 (1993)
98.	Kuwabara et al., "A C. elegans patched gene, ptc-1, functions in germ-line cytokinesis," <i>Genes and Development</i> , 14(15):1933-1944 (2000)
99.	Lin et al., "A Novel mRNA-crRNA Interference Phenomenon for Silencing bcl-2 Expression in Human LNCaP Cells," <i>Biochemical and Biophysical Research Communications</i> , 281, 639-644 (2001)
100.	Lin et al., "Policing rogue genes," <i>Nature</i> , 402, 128-129 (1999)
101.	Martinez et al., "Single-Stranded Antisense siRNAs Guide Target RNA Cleavage in RNAi," <i>Cell</i> 110:563-574 (2002)
102.	Mattick, John S., "The Functional Genomics of Noncoding RNA", <i>Science</i> , 309, 1527-1528 (2005)
103.	McCaffrey et al., "RNA interference in adult mice," <i>Nature</i> , 148, 38-39 (2002)
104.	Monia et al., "Evaluation of 2'-Modified Oligonucleotides Containing 2'-Deoxy Gaps as Antisense Inhibitors of Gene Expression," <i>J. Biol. Chem.</i> 268:14514-14522 (1993)
105.	Morvan et al., "Comparative Evaluation of Seven Oligonucleotide Analogues as Potential Antisense Agents," <i>J. Med. Chem.</i> , 36, 280-287 (1993)
106.	Olie et al., "Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide," <i>Biochimica et Biophysica Acta</i> , 1576, 101-109 (2002)
107.	Opalinska et al., "Nucleic-Acid Therapeutics: Basic Principles and Recent Applications," <i>Nature Reviews Drug Discovery</i> , (1):503-514 (2002)
108.	Parrish, "Functional Anatomy of a dsRNA Trigger: Differential Requirement for the Two Trigger Strands in RNA Interference," <i>Molecular Cell</i> 6:1077-1087 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

<b>FORM PTO-1449</b> <b>(Rev. 2-32)</b>  <b>SUPPLEMENTAL INFORMATION DISCLOSURE</b> <b>STATEMENT BY APPLICANT</b>  (Use several sheets if necessary)	<b>U.S. Department of Commerce</b> <b>Patent and Trademark Office</b>	<b>Atty. Docket No.</b>  04-082-F (400/249US)	<b>Serial No.</b>  10/597,755
<b>Applicant:</b> Jadhav et al.		<b>Filing Date:</b> August 7, 2006	<b>Group:</b> 1645

109.	Schmidt et al., "Base and sugar requirements for RNA cleavage of essential nucleoside residues in internal loop B of the hairpin ribozyme: implications for secondary structure," <u>Nucleic Acids Research</u> 24:573-581 (1996)
110.	Sethupathy et al., "TarBase: A comprehensive database of experimentally supported animal microRNA targets," <u>RNA</u> , 12:192-197 (2006)
111.	Sharp et al., "RNAi and double-strand RNA," <u>Genes &amp; Development</u> , 13:139-141 (1999)
112.	Strauss, Evelyn, "Molecular Biology: Candidate 'Gene Silencers' Found," <u>Molecular Biology</u> , Vol. 286, No. 5441, p. 886 (1999) [sometimes mistakenly referred to as being published in <u>Science</u> ]
113.	Thomson et al., "Activity of hammerhead ribozymes containing non-nucleotidic linkers," <u>Nucleic Acids Research</u> 21:5600-5603 (1993) (MAY BE REFERRED TO AS THOMPSON)
114.	Tuschl et al., "Small Interfering RNAs: A Revolutionary Tool for Analysis of Gene Function and Gene Therapy," <u>Molecular Interventions</u> , 295, 3, 158-167 (2002)
115.	Tuschl et al., "Targeted mRNA Degradation by Double-Stranded RNA In Vitro," <u>Genes &amp; Development</u> 13: 3191-3197 (1999)
116.	Tuschl, "RNA Interference and Small Interfering RNAs," <u>Chembiochem</u> 2:239-245 (2001)
117.	Vickers et al., "Efficient Reduction of Target RNAs by Small Interfering RNA and RNase H-dependent Antisense Agents," <u>Journal of Biological Chemistry</u> , 278, 7108-7118 (2003)
118.	Waterhouse et al., "Virus resistance and gene silencing in plants can be induced by simultaneous expression of sense and antisense RNA," <u>Proc. Natl. Acad. Sci. USA</u> , 95, 13959-13964 (1998)
119.	Wianny and Zernicka-Goetz et al., "Specific Interference with Gene Function by Double-Stranded RNA in Early Mouse Development," <u>Nature Cell Biology</u> 2:70-75 (2000)
120.	Zamore et al., "RNAi: Double-Stranded RNA Directs the ATP-Dependent Cleavage of mRNA at 21 to 23 Nucleotide Intervals," <u>Cell</u> 101:25-33 (2000)

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.

FORM PTO-1449  
(Rev. 2-32)

U.S. Department of Commerce  
Patent and Trademark Office

Atty. Docket No.

04-082-F  
(400/249US)

Serial No.

10/597,755

**SUPPLEMENTAL INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use several sheets if necessary)

**Applicant:**

Jadhav et al.

**Filing Date:**

August 7, 2006

**Group:**

1645

121.	Zhang et al., "Single Processing Center Models for Human Dicer and Bacterial RNase III," <i>Cell</i> , 118:57-68 (2004)
------	----------------------------------------------------------------------------------------------------------------------------

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication.